LGND Q2 2018 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$90M+221.6% YoY

Gross Profit

$89M98.7% margin

Operating Income

$70M77.9% margin

Net Income

$73M81.3% margin

EPS (Diluted)

$2.99

QoQ Revenue Growth

+60.3%

Cash Flow

Operating Cash Flow

$74M

Free Cash Flow

$74M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$1.2B

Stockholders' Equity

$620M

Cash & Equivalents

$957M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$90M	$28M	+221.6%
Gross Profit	$89M	$27M	+228.2%
Operating Income	$70M	$13M	+439.2%
Net Income	$73M	$6M	+1107.7%

Revenue Segments

License Fees, Milestones, and Product, Other

$51M47%

License Fees

$48M44%

Material Sales, Captisol

$8M7%

Milestone

$2M2%

License Fees, Milestones, and Product, Other, Product, Other

$1M1%